144 related articles for article (PubMed ID: 7629998)
1. [Expression of E-cadherin in thyroid neoplastic tissues and its correlation with malignant and metastatic potential].
Naitoh A; Kobayashi S; Iwase H; Kuzushima T
Nihon Rinsho; 1995 Jul; 53(7):1619-22. PubMed ID: 7629998
[TBL] [Abstract][Full Text] [Related]
2. Blood group antigens in differentiated thyroid neoplasms.
González-Cámpora R; García-Sanatana JA; Jordà i Heras MM; Salaverri CO; Vázquez-Ramírez FJ; Argueta-Manzano OE; Galera-Davidson H
Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin: a differentiation marker in thyroid malignancies.
Brabant G; Hoang-Vu C; Cetin Y; Dralle H; Scheumann G; Mölne J; Hansson G; Jansson S; Ericson LE; Nilsson M
Cancer Res; 1993 Oct; 53(20):4987-93. PubMed ID: 8402689
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
[TBL] [Abstract][Full Text] [Related]
5. Beta- and gamma-catenin expression in thyroid carcinomas.
Cerrato A; Fulciniti F; Avallone A; Benincasa G; Palombini L; Grieco M
J Pathol; 1998 Jul; 185(3):267-72. PubMed ID: 9771480
[TBL] [Abstract][Full Text] [Related]
6. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of preoperative DNA measurement on FNA in benign and malignant thyroid neoplasm.
Perigli G; Cicchi P; Cianchi F; Artusi R; Olivari D; Caldini A; Cortesini C
J Exp Clin Cancer Res; 1998 Mar; 17(1):113-6. PubMed ID: 9646245
[No Abstract] [Full Text] [Related]
8. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
9. Reduced nm 23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid.
Arai T; Watanabe M; Onodera M; Yamashita T; Masunaga A; Itoyama S; Itoh K; Sugawara I
Am J Pathol; 1993 Jun; 142(6):1938-44. PubMed ID: 8389529
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin gene alterations are rare events in thyroid tumors.
Soares P; Berx G; van Roy F; Sobrinho-Simões M
Int J Cancer; 1997 Jan; 70(1):32-8. PubMed ID: 8985087
[TBL] [Abstract][Full Text] [Related]
11. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities of the E-cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant.
Rocha AS; Soares P; Seruca R; Máximo V; Matias-Guiu X; Cameselle-Teijeiro J; Sobrinho-Simões M
J Pathol; 2001 Jul; 194(3):358-66. PubMed ID: 11439369
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of acidic and basic fibroblast growth factors in human benign and malignant thyroid lesions.
Kodama M; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Jpn J Clin Oncol; 1994 Apr; 24(2):66-73. PubMed ID: 7512670
[TBL] [Abstract][Full Text] [Related]
14. Pancreas cancer-associated antigen (PCAA) in medullary thyroid carcinoma.
Ueno K; Kobayashi T; Shimano T; Matsuura N; Monden T; Takeda T; Tomita N; Mori T
Med J Osaka Univ; 1994 Sep; 43(1-4):17-21. PubMed ID: 7609706
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin/α-catenin deregulated co-expression in thyroid carcinoma based on tissue microarray digital image analysis.
Tsiambas E; Ragos V; Georgakopoulos G; Rigopoulos DN; Fotiades PP; Chatziioannidis A; Stamatelopoulos A; Vilaras G; Karameris A
J BUON; 2016; 21(2):450-5. PubMed ID: 27273957
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of E-cadherin expression in thyroid neoplasms.
Naito A; Iwase H; Kuzushima T; Nakamura T; Kobayashi S
J Surg Oncol; 2001 Mar; 76(3):176-80. PubMed ID: 11276021
[TBL] [Abstract][Full Text] [Related]
18. Mixed medullary-follicular and medullary-papillary carcinoma of the thyroid: one or two entities?
Michal M; Curík R; Macák J; Ludvíková M; Dĕdic K
Zentralbl Pathol; 1993 Nov; 139(4-5):333-5. PubMed ID: 8130165
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
20. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas.
Motti ML; Califano D; Baldassarre G; Celetti A; Merolla F; Forzati F; Napolitano M; Tavernise B; Fusco A; Viglietto G
Carcinogenesis; 2005 Jun; 26(6):1021-34. PubMed ID: 15718252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
